Lipitor does not prevent narrowing in heart valve

Key points
- The popular cholesterol-reducing drug Lipitor made by Pfizer does not prevent obstruction of the heart valve that leads to the aorta, the body's largest artery, according to study findings published in The New England Journal of Medicine.
- In a study conducted to determine whether the drug, also known by its generic name atorvastatin, did more than just reduce cholesterol, doctors found that Lipitor failed to prevent obstructions that can keep the heart from pumping blood adequately.
- The condition, known as calcified aortic stenosis, occurs when a key heart valve narrows or becomes blocked, preventing the heart from pumping blood properly and can manifest itself in spite of reductions of cholesterol levels, according to the study.
- Aortic stenosis affects 3 percent of adults over 75, making it the most common valve defect in North America and Europe and occurs gradually over several decades.
The popular cholesterol-reducing drug Lipitor made by Pfizer does not prevent obstruction of the heart valve that leads to the aorta, the body's largest artery, according to study findings published in The New England Journal of Medicine.
In a study conducted to determine whether the drug, also known by its generic name atorvastatin, did more than just reduce cholesterol, doctors found that Lipitor failed to prevent obstructions that can keep the heart from pumping blood adequately.
The condition, known as calcified aortic stenosis, occurs when a key heart valve narrows or becomes blocked, preventing the heart from pumping blood properly and can manifest itself in spite of reductions of cholesterol levels, according to the study.
Surgery is usually required to fix it.
Aortic stenosis affects 3 percent of adults over 75, making it the most common valve defect in North America and Europe and occurs gradually over several decades. By the time symptoms appear, surgery is typically needed to repair or replace the valve.
As part of the study, 155 volunteers with signs of calcified aortic stenosis were given a placebo or Lipitor, which like other drugs known as statins slow the narrowing of small heart arteries caused by heart disease.
After a little more than two years, the team led by Joanna Cowell of Royal Infirmary in Edinburgh found that the drug brought cholesterol levels down as expected but produced no real improvement as far as obstructions are concerned.
"Aortic stenosis progresses despite intensive reductions in serum cholesterol concentrations," the Cowell team concluded.
The study was funded in part by an educational award from Pfizer, a grant from the British Heart Foundation and the Welcome Trust Clinical Resource Facility in Scotland.
In journal editorial, Raphael Rosenhek of the Vienna General Hospital in Austria agreed, saying that prescribing statins "is not justified" unless a patient has another, more established, reason for taking the medicine.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Heart & Blood Vessels →
NewsClosing hole in the heart no better than drugs in preventing strokes
Loyola University Medical Center is one of the major enrollers in a landmark clinical trial that found that plugging a hole in the heart works no better than drugs in preventing strokes. The study is published in the…
18 March 2012
NewsHot Topics in Heart Disease Prevention and Treatment
From prevention to treatment, cardiovascular medicine is changing rapidly. During Heart Disease Awareness Month, experts at the University of Michigan Cardiovascular Center are available to discuss new strategies for…
17 February 2012
NewsHow to Prevent 500,000 Heart Attacks a Year
Why is cardiovascular disease still the number one killer in the Western World when risk factors are well known and risk-reduction strategies are widely available? The Screening for Heart Attack Prevention and Education…
2 February 2012




